| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
As a lipid excipient, DSPE-succinic acid does not have a specific biological receptor target. Its primary function is as a structural component of liposomes and nanoparticles. The carboxylic acid moiety provides a reactive handle for conjugation to amine-containing molecules (e.g., proteins, peptides, targeting ligands) in the presence of an activating agent such as EDC or HATU, forming a stable amide linkage. This allows for the functionalization of liposomes for targeted drug delivery.
|
|---|---|
| ln Vitro |
In vitro, DSPE-succinic acid is used in the preparation of nanoparticles or liposomes for drug delivery. The carboxylic acid group can be used to conjugate targeting ligands or therapeutic agents, enabling the creation of functionalized nanocarriers. The compound's ability to form stable lipid bilayers makes it a valuable component for encapsulating and delivering therapeutics such as mRNA or DNA vaccines.
|
| ln Vivo |
In vivo, DSPE-succinic acid-containing liposomes and nanoparticles are used for drug delivery applications. The functionalized nanoparticles can be used to deliver therapeutics to specific tissues or cells. The compound itself is an excipient and does not have intrinsic biological activity, but it enables the creation of targeted and effective drug delivery systems.
|
| Enzyme Assay |
In vitro assays for DSPE-succinic acid typically involve characterizing the formation and functionalization of liposomes or nanoparticles. Liposomes are prepared by dissolving the lipid components in organic solvent, followed by solvent removal and hydration. The successful incorporation of DSPE-succinic acid and the availability of the carboxylic acid group for conjugation can be verified using methods such as dynamic light scattering (DLS) for size and zeta potential, and by using colorimetric assays to quantify carboxylic acid groups.
|
| Cell Assay |
In vitro cellular assays for DSPE-succinic acid are typically performed as part of drug delivery studies. Cells are treated with liposomes or nanoparticles formulated with the lipid, and their uptake, cytotoxicity, and therapeutic efficacy are assessed. The carboxylic acid group can be used to conjugate fluorescent probes or targeting ligands to track cellular uptake and targeting efficiency.
|
| Animal Protocol |
In vivo animal studies for DSPE-succinic acid-containing formulations typically involve the administration of the nanoparticles to rodent models to assess their pharmacokinetics, biodistribution, and therapeutic efficacy. The formulations can be used to deliver a variety of therapeutic agents, including nucleic acids and small molecule drugs.
|
| ADME/Pharmacokinetics |
DSPE-succinic acid has a molecular weight of 848.14 and a molecular formula of C45H86NO11P. It is soluble in DMF at 3.33 mg/mL (3.93 mM) with ultrasonic warming to 60°C. The compound is typically stored at -20°C. Detailed pharmacokinetic parameters are not applicable as the compound is an excipient.
|
| Toxicity/Toxicokinetics |
There is no specific toxicity data reported for DSPE-succinic acid in the available literature. As a research chemical, it should be handled with standard safety precautions. Phospholipids are generally considered biocompatible and low in toxicity. The compound is not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
The role of folate-targeted liposomal doxorubicin (FTL-Dox) in folate receptor (FR)-overexpressing tumors in vitro has been well characterized, particularly in human KB cancer cells. However, studies evaluating the in vivo efficacy of FTL-Dox in a KB mouse xenograft model are scarce. This study investigated the antitumor activity of intravenously administered FTL-Dox in KB-bearing tumor-bearing mice. We synthesized a folate ligand composed of folate-polyethylene glycol-distearate phosphatidylethanolamine (FA-PEG-DSPE) and used polyethylene glycol (PEG) of varying molecular weights. To design the optimal FTL-Dox formulation for therapeutic studies, we prepared multiple FTLs and characterized their in vitro targeting and in vivo tissue biodistribution. Mice received a single intravenous injection of free doxorubicin, untargeted PEGylated liposomal doxorubicin (PL-Dox), or FTL-Dox, respectively. Although FTL was cleared from the circulatory system more rapidly, FTL and PL accumulated similarly in tumor tissues. Mice treated with FTL-Dox 20 mg/kg showed slightly higher tumor growth inhibition than mice treated with PL-Dox 20 mg/kg, and their lifespan was extended by nearly 50% (P = 0.0121; log-rank test). We conclude that systemically administered FTLs have the potential to enhance in vivo anticancer drug delivery; however, to realize the benefits of tumor-targeted therapy, it may be necessary to block the clearance of FTLs by normal tissues expressing FRs. [1]
DSPE-succinic acid is a phospholipid with a carboxylic acid moiety, used to prepare nanoparticles or liposomes for drug delivery. It has a molecular formula of C45H86NO11P and a molecular weight of 848.14. The carboxylic acid group allows for conjugation to amine-containing molecules, enabling the creation of functionalized drug delivery systems. |
| Molecular Formula |
C45H86NO11P
|
|---|---|
| Molecular Weight |
848.138216495514
|
| Exact Mass |
847.593
|
| CAS # |
248253-94-3
|
| PubChem CID |
54608655
|
| Appearance |
Typically exists as White to off-white solid at room temperature
|
| LogP |
14.4
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
47
|
| Heavy Atom Count |
58
|
| Complexity |
1040
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)CCC(=O)O)OC(=O)CCCCCCCCCCCCCCCCC
|
| InChi Key |
YHASCFOFGLKNAQ-VQJSHJPSSA-N
|
| InChi Code |
InChI=1S/C45H86NO11P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-44(50)54-39-41(40-56-58(52,53)55-38-37-46-42(47)35-36-43(48)49)57-45(51)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h41H,3-40H2,1-2H3,(H,46,47)(H,48,49)(H,52,53)/t41-/m1/s1
|
| Chemical Name |
4-[2-[[(2R)-2,3-di(octadecanoyloxy)propoxy]-hydroxyphosphoryl]oxyethylamino]-4-oxobutanoic acid
|
| Synonyms |
DSPE-succinic acid; 248253-94-3; NSC671619; SCHEMBL22788417; NSC-671619;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1791 mL | 5.8953 mL | 11.7905 mL | |
| 5 mM | 0.2358 mL | 1.1791 mL | 2.3581 mL | |
| 10 mM | 0.1179 mL | 0.5895 mL | 1.1791 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
